Mirum Pharmaceuticals, Inc. filings document operating results, product-sales disclosures, clinical program updates and governance matters for a rare disease biopharmaceutical company. Its 8-K reports furnish earnings releases, preliminary sales information, Regulation FD investor materials and other event disclosures tied to LIVMARLI, CHOLBAM, CTEXLI and investigational programs such as volixibat and brelovitug.
The company’s SEC record also covers capital-structure and transaction disclosures, including the completed Bluejay Therapeutics acquisition, related pro forma financial information and a PIPE financing. Proxy filings describe annual meeting matters, board elections, executive compensation and equity-plan governance, while registration details identify Mirum common stock as listed on the Nasdaq Global Market under MIRM.
Mirum Pharmaceuticals files a shelf registration to permit resale of up to 8,960,998 shares of its common stock. The prospectus covers resale by selling stockholders of 8,960,998 shares, which include shares issued in connection with the January 23, 2026 acquisition of Bluejay, shares held back as indemnity, private placement shares and shares issuable upon exercise of pre-funded warrants.
The company states it will not receive proceeds from these resales and agreed to bear registration expenses; selling stockholders will pay distribution-related fees and commissions. The offering is for resale by holders and is subject to lock-ups and exercise limitations described in the prospectus.
Mirum Pharmaceuticals, Inc. files its annual report describing a focused rare-disease biopharma platform built around bile-acid and CNS therapies. The company highlights three approved medicines—Livmarli for Alagille syndrome and PFIC, Ctexli for cerebrotendinous xanthomatosis, and Cholbam for bile acid and peroxisomal disorders—commercialized mainly in the U.S., Canada and parts of Europe.
Mirum details a broad late-stage pipeline, including volixibat for PSC and PBC with multiple Phase 2b readouts expected in 2026, brelovitug for chronic hepatitis D in the global Phase 3 AZURE program, and MRM-3379 for fragile X syndrome in Phase 2 with data expected in 2027. The report also outlines recent business development, including the Travere bile-acid portfolio acquisition and the Bluejay Therapeutics acquisition, extensive license and royalty structures with Shire/Takeda, Pfizer, Sanofi, Novartis and Enthorin, and a large global patent estate with protection for key programs into the 2030s and 2040s.
Mirum Pharmaceuticals reported strong 2025 growth while remaining loss-making. Net product sales rose to $521.3 million from $336.4 million, driven by LIVMARLI at $360.0 million and bile acid medicines at $161.3 million. For 2026, the company guides to global net product sales of $630 million to $650 million.
Total operating expenses increased to $543.4 million from $424.5 million, including $95.0 million of non-cash items, leading to a narrowed full-year net loss of $23.4 million versus $87.9 million in 2024. Unrestricted cash, cash equivalents and investments were $391.4 million as of December 31, 2025, up from $292.8 million, supported by two private placements totaling $268.5 million.
The update highlights multiple late-stage catalysts in 2026, including volixibat VISTAS topline data in PSC in Q2 2026, LIVMARLI EXPAND topline data in Q4 2026, volixibat VANTAGE enrollment completion in H2 2026, and brelovitug AZURE topline HDV data in H2 2026, alongside progress with CTEXLI and MRM-3379.
Mirum Pharmaceuticals director Saira Ramasastry reported an option exercise and share sale. On February 13, 2026, she exercised stock options covering 2,000 shares of common stock at an exercise price of $23.51 per share, converting a derivative position into shares.
On the same day, she then sold 2,000 shares of common stock in an open-market transaction at a price of $102.09 per share, leaving 0 common shares owned directly after the sale and 6,000 stock options held directly. The filing states the sale occurred under a Rule 10b5-1 trading plan adopted on September 18, 2025, and notes that the stock option involved is fully vested.
Janus Henderson Group plc, through its investment adviser subsidiaries, reports beneficial ownership of 6,065,308 shares of Mirum Pharmaceuticals, Inc. common stock, representing 11.8% of the class as of 12/31/2025.
The shares are held in various managed portfolios, where Janus Henderson’s asset managers exercise shared voting and dispositive power but do not have rights to receive dividends or sale proceeds. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Mirum Pharmaceuticals.
Mirum Pharmaceuticals (MIRM) shareholder Saira Ramasastry has filed a Form 144 indicating an intent to sell 2,000 shares of common stock. The planned sale is to be executed through Morgan Stanley Smith Barney LLC, with an aggregate market value of $204,180.00 and an approximate sale date of 02/13/2026 on the NASDAQ.
The 2,000 shares were acquired on 02/13/2026 via a stock option exercise from the issuer, paid in cash. The notice also lists prior sales over the past three months, including 2,000 common shares sold on 01/15/2026 for $181,980.00, 5,000 shares on 12/22/2025 for $400,000.00, and 2,000 shares on 12/18/2025 for $139,460.00. Shares of common stock outstanding were 51,393,574 as of the filing details, a baseline figure separate from the planned sale amount.
Mirum Pharmaceuticals, Inc. received an amended Schedule 13G showing that Eventide Asset Management, LLC, together with Finny Kuruvilla and Robin C. John, reports beneficial ownership of 2,093,582 shares of common stock, representing 4.1% of the class. Eventide has sole voting and dispositive power over these shares, while Kuruvilla and John report shared voting and dispositive power over the same amount. The group states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Mirum. The filers also expressly disclaim beneficial ownership of the securities covered by the statement and make a joint filing agreement under Rule 13d-1(k)(1).
Mirum Pharmaceuticals President and COO Peter Radovich reported a sale of company common stock in a Form 4 filing. On February 2, 2026, he sold 2,631 shares of common stock at an average price of $103.3035 per share. According to the footnote, the shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. After this transaction, he beneficially owned 20,655 shares of Mirum Pharmaceuticals common stock directly.
Mirum Pharmaceuticals, Inc.’s chief executive officer and director Christopher Peetz reported a sale of 9,108 shares of common stock on February 2, 2026 at a price of $103.3035 per share. The filing states these shares were sold to cover tax withholding obligations from vesting restricted stock units.
After this transaction, Peetz beneficially owned 160,294 Mirum common shares directly and 187,500 shares indirectly through The Peetz Family Trust. This reflects a routine, tax-related insider transaction rather than an open-market discretionary sale.
Mirum Pharmaceuticals SVP and Global Controller Jolanda Howe reported routine equity compensation activity. On January 31, 2026, 1,771 restricted stock units vested and were converted into an equal number of common shares at an exercise price of $0.
On February 2, 2026, Howe sold 968 shares of common stock at a price of $103.3035 per share to cover tax withholding obligations related to the vesting. After these transactions, Howe directly owned 4,503 shares of Mirum Pharmaceuticals common stock.